ECSP055575A - Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel. - Google Patents

Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.

Info

Publication number
ECSP055575A
ECSP055575A EC2005005575A ECSP055575A ECSP055575A EC SP055575 A ECSP055575 A EC SP055575A EC 2005005575 A EC2005005575 A EC 2005005575A EC SP055575 A ECSP055575 A EC SP055575A EC SP055575 A ECSP055575 A EC SP055575A
Authority
EC
Ecuador
Prior art keywords
treatment
skin diseases
thio
oxindol derivatives
oxindol
Prior art date
Application number
EC2005005575A
Other languages
English (en)
Inventor
Andrew Fensome
Diane Deborah Harrison
Richarg Craing Winneker
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP055575A publication Critical patent/ECSP055575A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • A61Q7/02Preparations for inhibiting or slowing hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona métodos para el tratamiento de enfermedades de la piel, el cual incluye la administración a un mamífero de una composición que contiene un compuesto de fórmula I, o tautómeros del mismo, en un régimen donde la fórmula I es como se muestra y donde R1-R5 y Q1 son definidos como se describe aquí. Específicamente se describen métodos para el tratamiento del acné, el hirsutismo y una composición para acondicionar la piel.
EC2005005575A 2002-06-25 2005-01-25 Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel. ECSP055575A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39191302P 2002-06-25 2002-06-25

Publications (1)

Publication Number Publication Date
ECSP055575A true ECSP055575A (es) 2005-04-18

Family

ID=30000776

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005575A ECSP055575A (es) 2002-06-25 2005-01-25 Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.

Country Status (17)

Country Link
US (1) US7115649B2 (es)
EP (1) EP1515680A4 (es)
JP (1) JP2005535625A (es)
KR (1) KR20050012831A (es)
CN (1) CN1662206A (es)
AR (1) AR040338A1 (es)
AU (1) AU2003258952A1 (es)
BR (1) BR0312092A (es)
CA (1) CA2489810A1 (es)
EC (1) ECSP055575A (es)
IL (1) IL165394A0 (es)
MX (1) MXPA04012418A (es)
NO (1) NO20045215L (es)
RU (1) RU2005101624A (es)
TW (1) TW200401637A (es)
WO (1) WO2004000227A2 (es)
ZA (1) ZA200410401B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CA2489813A1 (en) * 2002-06-25 2003-12-31 Wyeth Use of thio-oxindole derivatives in treatment of hormone-related conditions
WO2005100346A1 (en) 2004-04-08 2005-10-27 Wyeth Thioamide derivatives as progesterone receptor modulators
ATE409699T1 (de) * 2004-04-08 2008-10-15 Wyeth Corp Verfahren zur minimierung von thioamidverunreinigungen
AU2005237520B2 (en) 2004-04-27 2012-01-19 Wyeth Purification of progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008088771A2 (en) * 2007-01-12 2008-07-24 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
CN101636157A (zh) * 2007-01-12 2010-01-27 康乃尔研究基金会有限公司 作为抗菌干预的新型靶的腺苷酰环化酶
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
RU2015103694A (ru) 2009-10-14 2015-06-27 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
MX343215B (es) 2010-02-26 2016-10-27 Xenon Pharmaceuticals Inc Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos.
KR101278271B1 (ko) * 2011-08-02 2013-06-25 충남대학교산학협력단 인돌린-2-티온 유사체를 함유한 미백용 조성물
US9737522B2 (en) 2012-08-09 2017-08-22 Emory University NMDA receptor modulators and uses related thereto
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169198A (en) * 1875-10-26 Improvement in treating quicksilver-ore
US92711A (en) * 1869-07-20 e d w a r d s
WO1985000519A1 (en) * 1983-07-29 1985-02-14 Duke University Method of treating androgen-related disorders
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
IL142598A0 (en) * 1998-10-23 2002-03-10 Aventis Pharma Gmbh Preparations for topical application of substances having antiandrogenic effect
AU760964B2 (en) * 1998-12-31 2003-05-22 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
EP1206761B1 (en) 1999-08-26 2007-10-03 Automotive Systems Laboratory Inc. Magnetic sensor
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7119207B2 (en) * 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
YU73902A (sh) 2000-04-10 2005-09-19 Pfizer Products Inc. Jedinjenja koja sadrže benzoamid-piperidin i srodna jedinjenja
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP4976849B2 (ja) * 2004-07-12 2012-07-18 ローム株式会社 半導体発光素子

Also Published As

Publication number Publication date
US20040006122A1 (en) 2004-01-08
US7115649B2 (en) 2006-10-03
TW200401637A (en) 2004-02-01
RU2005101624A (ru) 2005-06-27
WO2004000227A2 (en) 2003-12-31
NO20045215L (no) 2005-03-17
JP2005535625A (ja) 2005-11-24
BR0312092A (pt) 2005-03-22
IL165394A0 (en) 2006-01-15
EP1515680A2 (en) 2005-03-23
ZA200410401B (en) 2006-05-31
KR20050012831A (ko) 2005-02-02
AR040338A1 (es) 2005-03-30
MXPA04012418A (es) 2005-04-19
WO2004000227A3 (en) 2004-04-08
CN1662206A (zh) 2005-08-31
CA2489810A1 (en) 2003-12-31
EP1515680A4 (en) 2005-09-21
AU2003258952A1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
ECSP055575A (es) Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.
ECSP055572A (es) Derivados ciclotiocarbamativos como moduladores pr y el uso de los mismos en el tratamiento de enfermedades de la piel.
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
CR10874A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3 metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro benzonitrilo y metodos para el uso de los mismos
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
MY157661A (en) Bendamustine pharmaceutical compositions
PA8680701A1 (es) Derivados de oxindol
UY33616A (es) Compuestos con estructura de imidazotriazinona
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
AR052322A1 (es) Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica
UY29417A1 (es) Agentes endoparasiticidas
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
ECSP088472A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
CO6430466A2 (es) Derivados de pirazolopirimidina triciclicos